GET DAILY SIGNALSSeer (SEER) Readies Q3 2026 Earnings Report: Key Details to Watch
Key Takeaways
- Seer, Inc. (SEER) is scheduled to report third-quarter 2026 results after the market close on Tuesday, November 10, 2026, with a conference call at 4:30 p.m. Eastern Time.
- Wall Street consensus calls for a net loss of -$0.26 per share on revenue of roughly $4.15 million, implying essentially flat year-over-year top-line growth of about 0.7%.
- A year earlier, in the third quarter of 2025, Seer posted a loss of -$0.32 per share on $4.12 million in revenue, so the consensus reflects a modestly narrower expected loss.
- Seer last reported in August, posting a loss of -$0.31 per share on $3.10 million in revenue, which missed the -$0.27 consensus and marked a 23.4% revenue decline.
- Investors will be watching whether management reaffirms its full-year 2026 revenue outlook of $16 million to $18 million, which was reiterated last quarter.
- Seer has topped the consensus earnings-per-share (EPS) estimate in five of its last eight quarters, adding context to how the stock may respond to results.
- For additional context, explore Seer's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- You can also explore Trending AI Robots for additional market insight.
Why This Quarter Matters for Seer
Seer focuses on proteomics, offering tools that deliver deep, unbiased insights into proteins for researchers and biopharma partners. As the company remains in an early commercialization stage, its quarterly updates carry particular weight. Revenue trends, instrument and consumables demand, and cash management stand out as critical areas. Recent results have been uneven, with revenue falling 23.4% year over year in the second quarter of 2026 after a 33.6% drop in the first quarter. The upcoming report offers a chance to assess whether demand is finding firmer footing and whether losses continue to narrow without altering the full-year outlook.
Consensus Estimates and Historical Context
Analysts project a net loss of -$0.26 per share for the third quarter of 2026, narrower than the -$0.32 loss from the same period last year. Revenue is expected near $4.15 million, compared with $4.12 million a year earlier, pointing to roughly flat growth. Management’s reaffirmed full-year 2026 revenue range of $16 million to $18 million will likely draw attention as a signal that the second-half path remains on track. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Looking back, Seer missed the consensus EPS estimate last quarter with a -$0.31 loss versus the expected -$0.27, while revenue of $3.10 million fell short of forecasts. Even so, the company has beaten EPS estimates in five of the past eight quarters. Beyond the top-line numbers, investors will focus on gross margins, operating expenses, cash usage, and updates on instrument placements along with consumables revenue, which help gauge commercial progress.
Investor Sentiment Heading Into the Report
Caution appears to be the prevailing mood. Shares have traded toward the lower end of their recent range after consecutive revenue declines and the recent EPS miss. Past earnings reactions have generally been muted or slightly negative, with modest single-digit moves in several cases, though one earlier report triggered a sharper decline. Attention seems centered less on the expected loss itself and more on signs of revenue stabilization and confirmation of full-year guidance. Potential concerns include softer instrument sales, longer sales cycles, or any slowdown in consumables demand from research and biopharma customers.
What Comes Next After the Release
Once the third-quarter numbers are out, focus will turn to the fourth quarter and the company’s ability to finish the year inside its stated revenue band. Instrument placements and the recurring revenue they generate remain central to the longer-term story. Commentary on customer adoption, repeat business, and account expansion will likely carry more weight than the quarterly loss figure. Cost discipline also merits watching, as narrower losses and controlled cash burn can extend the runway while still supporting necessary commercial efforts. Industry-wide factors such as research funding cycles and broader economic conditions may influence spending patterns as well. Any guidance updates or partnership news could further shape the outlook.
Using AI Tools in My Research Process
When preparing analysis like this, I often rely on Tickeron’s AI Screener to quickly filter peers in the life sciences space and review technical and fundamental signals side by side. It helps surface comparable names and spot shifts in market conditions without manual effort, giving a clearer view of where SEER stands relative to the group.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SEER's Stochastic Oscillator is staying in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SEER's RSI Indicator exited the oversold zone, 28 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEER advanced for three days, in 162 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
SEER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SEER as a result. In 75 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SEER turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 44 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
SEER moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SEER crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for SEER entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (3.498). P/E Ratio (-1.336) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.800) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. SEER’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement